Clinical Commander

Back to dossier
endo.men1.core.v1PRODUCTION
endo.men1.core.v1

Multiple endocrine neoplasia type 1 (MEN1)

endocrinologychronicsyndromeadultpediatric
Hard-required inputs
0 / 10
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Establish whether MEN1 diagnostic criteria are met — (1) ≥2 of 3 main tumors, (2) 1 main tumor + first-degree relative with MEN1, or (3) germline MEN1 mutation; distinguish clinical vs genetically-confirmed vs at-risk carrier (Thakker JCEM 2012)

Inputs
2
Actions
0
Advance rule
Set
Advance when

MEN1 status classified — confirmed (clinical or genetic), at-risk carrier, or differential

Patient inputs (16)

Penetrance is age-dependent; surveillance start ages differ by tumor (pHPT from ~8 y, pituitary/pNET from ~5-10 y per MEN1 CPG); youngest age of presentation drives index of suspicion (Thakker JCEM 2012)

Autosomal-dominant; first-degree relative with MEN1 satisfies a diagnostic criterion and triggers cascade genetic testing (Thakker JCEM 2012)

PPIs falsely elevate gastrin / chromogranin A; thiazide/lithium confound calcium; reconciliation required before interpreting screens (Thakker JCEM 2012)

Identified germline MEN1 mutation is itself diagnostic (asymptomatic carrier) and defines the surveillance cohort (Thakker JCEM 2012)

Hypercalcemia is the earliest and most common MEN1 manifestation (pHPT ~90-95%); albumin-corrected or ionized calcium anchors the parathyroid axis (Thakker JCEM 2012)

Non-suppressed PTH with hypercalcemia confirms pHPT; multiglandular pattern is characteristic of MEN1 (Thakker JCEM 2012)

Elevated fasting gastrin (off PPI where safe, or with secretin stimulation) screens for gastrinoma / Zollinger-Ellison (Thakker JCEM 2012; ENETS)

72-h fast with paired glucose / insulin / C-peptide / proinsulin diagnoses insulinoma (endogenous hyperinsulinemic hypoglycemia) (Thakker JCEM 2012)

Prolactinoma is the most common MEN1 pituitary tumor; prolactin anchors the pituitary axis (Thakker JCEM 2012)

IGF-1 (with GH if elevated) screens for somatotroph adenoma / acromegaly (Thakker JCEM 2012)

Periodic gadolinium pituitary MRI detects micro/macroadenoma and mass effect (Thakker JCEM 2012 surveillance)

Cross-sectional pancreas imaging (MRI/CT) ± EUS detects pNETs; complements biochemistry for non-functioning tumors (Thakker JCEM 2012; ENETS)

Chest CT/MRI screens for thymic carcinoid — a leading MEN1-specific cause of death, aggressive in male smokers (Thakker JCEM 2012)

Male smokers with MEN1 are at highest risk for aggressive thymic carcinoid; modifies surveillance intensity and cessation counseling (Thakker JCEM 2012)

Hypercalcemia and prolactinoma management change in pregnancy; gadolinium and certain agents are limited (Thakker JCEM 2012)

General neuroendocrine tumor marker for pancreatic / foregut carcinoid surveillance (interpret off PPI; Thakker JCEM 2012; ENETS)

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (6)

6 need judgement
  • informationallife_threateninghypercalcemic_crisis_men1
    MEN1 pHPT with calcium >14 mg/dL and AKI / altered mental status / arrhythmia
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateninginsulinoma_neuroglycopenia
    Endogenous hyperinsulinemic hypoglycemia with neuroglycopenic symptoms (confusion, seizure, loss of consciousness)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningpituitary_apoplexy_mass_effect
    Pituitary macroadenoma with apoplexy, acute visual loss, or chiasmal compression
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverecomplicated_zollinger_ellison
    Gastrinoma with refractory ulcer disease, GI hemorrhage, or perforation
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalsevereaggressive_thymic_carcinoid
    Thymic carcinoid detected on chest imaging (invasive/large), especially male smoker
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseveremetastatic_functional_pNET
    Functional pancreatic NET with metastatic disease or rapid growth (>2 cm / G2-G3)
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RED_FLAGSrequiredDrives severity classification
Loading…

Recommended regimen

MEN1 organ-directed ladder (parathyroid → gastrinoma → insulinoma → pituitary → carcinoid surveillance/resection)
axis: men1_organ_directedstep 1 - Step 1 — Primary hyperparathyroidism (multiglandular)
Selected step "Step 1 — Primary hyperparathyroidism (multiglandular)" — Hypercalcemia + non-suppressed PTH (earliest, ~90-95% lifetime; nearly always multiglandular)
  • subtotal or total parathyroidectomy with cryopreservation
    first line
    endocrine_surgery
    surgical
    triggers: symptomatic_or_criteria_met_pHPT, multiglandular_disease
    Thakker JCEM 2012 — MEN1 pHPT is multiglandular; less-than-subtotal resection has high recurrence. Subtotal (3.5-gland) or total parathyroidectomy with transcervical thymectomy + parathyroid tissue cryopreservation; balance recurrence vs permanent hypoparathyroidism
  • cinacalcet
    second line
    calcimimetic
    30 mg • PO • daily, titrate to BID
    triggers: non_surgical_candidate, persistent_or_recurrent_pHPT, awaiting_surgery
    Thakker JCEM 2012 — lowers calcium when surgery deferred/declined or for persistent disease; does not treat the underlying multiglandular hyperplasia
    rxcui 407990
  • cholecalciferol
    add on
    vitamin_D
    1000-2000 IU • PO • daily
    triggers: vitamin_D_deficiency
    Thakker JCEM 2012 — cautious repletion of concomitant vitamin D deficiency optimizes interpretation and bone health
    rxcui 2418

outpatient playbook — drug actions (5)

  1. 1. germline MEN1 testing + counseling
    sequencing + MLPA; cascade first-degree relatives • genetic • once (index), then cascade
    trigger: Index case or affected relative
    Defines surveillance cohort (Thakker JCEM 2012)
  2. 2. cinacalcet
    30 mg, titrate to BID • PO • daily/BID
    trigger: Non-surgical or recurrent pHPT
    Calcium control when surgery deferred (Thakker JCEM 2012)
  3. 3. omeprazole (high-dose PPI)
    60 mg, titrate • PO • daily-BID
    trigger: Gastrinoma / Zollinger-Ellison
    First-line; surgery controversial in MEN1 (Thakker JCEM 2012)
  4. 4. cabergoline
    0.25-0.5 mg, titrate • PO • twice weekly
    trigger: Prolactinoma
    First-line before surgery (Thakker JCEM 2012)
  5. 5. octreotide LAR
    20 mg • IM • monthly
    trigger: Unresectable functional NET / acromegaly / foregut carcinoid
    Symptom + antiproliferative control (ENETS)

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: First-degree relative with MEN1 / known germline MEN1 mutation — cascade screening (Thakker JCEM 2012); Primary hyperparathyroidism, especially age <40 or multiglandular disease (Thakker JCEM 2012); Two or more of parathyroid / pancreatic-duodenal NET / pituitary tumors (Thakker JCEM 2012 diagnostic criteria).

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Multiple endocrine neoplasia type 1 (MEN1)** (endo.men1.core.v1).
Phenotype framing: Resolve MEN1 vs MEN2A/2B (no MTC or pheochromocytoma in MEN1; RET vs MEN1 gene), MEN4 (CDKN1B), familial isolated hyperparathyroidism, hyperparathyroidism-jaw-tumor (CDC73), familial hypocalciuric hypercalcemia, sporadic single-gland adenoma, and non-syndromic pNET/prolactinoma (Thakker JCEM 2012)
Scope: Establish whether MEN1 diagnostic criteria are met — (1) ≥2 of 3 main tumors, (2) 1 main tumor + first-degree relative with MEN1, or (3) germline MEN1 mutation; distinguish clinical vs genetically-confirmed vs at-risk carrier (Thakker JCEM 2012)

No severity triggers fired against current inputs.

Plan

Regimen axis: **MEN1 organ-directed ladder (parathyroid → gastrinoma → insulinoma → pituitary → carcinoid surveillance/resection)** — step "Step 1 — Primary hyperparathyroidism (multiglandular)".
1. subtotal or total parathyroidectomy with cryopreservation surgical (endocrine_surgery, first line) — Thakker JCEM 2012 — MEN1 pHPT is multiglandular; less-than-subtotal resection has high recurrence. Subtotal (3.5-gland) or total parathyroidectomy with transcervical thymectomy + parathyroid tissue cryopreservation; balance recurrence vs permanent hypoparathyroidism
2. cinacalcet 30 mg PO daily, titrate to BID (calcimimetic, second line) — Thakker JCEM 2012 — lowers calcium when surgery deferred/declined or for persistent disease; does not treat the underlying multiglandular hyperplasia
3. cholecalciferol 1000-2000 IU PO daily (vitamin_D, add on) — Thakker JCEM 2012 — cautious repletion of concomitant vitamin D deficiency optimizes interpretation and bone health

Setting playbook (outpatient) — Confirm/maintain MEN1 diagnosis, run lifelong multi-axis surveillance, coordinate genetic cascade, and select organ-directed therapy
4. germline MEN1 testing + counseling sequencing + MLPA; cascade first-degree relatives genetic once (index), then cascade — Index case or affected relative (Defines surveillance cohort (Thakker JCEM 2012))
5. cinacalcet 30 mg, titrate to BID PO daily/BID — Non-surgical or recurrent pHPT (Calcium control when surgery deferred (Thakker JCEM 2012))
6. omeprazole (high-dose PPI) 60 mg, titrate PO daily-BID — Gastrinoma / Zollinger-Ellison (First-line; surgery controversial in MEN1 (Thakker JCEM 2012))
7. cabergoline 0.25-0.5 mg, titrate PO twice weekly — Prolactinoma (First-line before surgery (Thakker JCEM 2012))
8. octreotide LAR 20 mg IM monthly — Unresectable functional NET / acromegaly / foregut carcinoid (Symptom + antiproliferative control (ENETS))

Non-pharmacologic actions:
- Endocrine surgery referral for pHPT meeting criteria — subtotal/total parathyroidectomy + cryopreservation (Thakker JCEM 2012)
- Surgical referral for localized insulinoma / large or growing pNET (Thakker JCEM 2012; ENETS)
- Thoracic surgery for detected thymic/bronchial carcinoid; consider prophylactic transcervical thymectomy at parathyroid surgery (Thakker JCEM 2012)
- Smoking cessation counseling (thymic-carcinoid risk) (Thakker JCEM 2012)
- Genetic counseling + cascade testing of first-degree relatives; offer from ~5-10 y depending on earliest familial tumor (Thakker JCEM 2012)

AVOID / contraindication checks:
- Correct hypercalcemia before interpreting/treating gastrinoma — high calcium worsens gastrin (Thakker JCEM 2012)
- Do not abruptly stop PPI in active Zollinger Ellison — rebound acid hypersecretion / perforation risk (Thakker JCEM 2012)
- Gastrinoma surgery controversial in MEN1 — multifocal duodenal tumors, low biochemical cure; PPI first (Thakker JCEM 2012)
- Less than subtotal parathyroidectomy has high recurrence in MEN1 — multiglandular disease (Thakker JCEM 2012)
- Cabergoline first line for prolactinoma before considering surgery (Thakker JCEM 2012)
- Cinacalcet — monitor calcium for hypocalcemia after titration (Thakker JCEM 2012)
- Limit gadolinium MRI and re risk dopamine agonist / calcimimetic dosing in pregnancy (Thakker JCEM 2012)
- Hold PPI per protocol before fasting gastrin / chromogranin A to avoid false elevation (ENETS)

Monitoring

Regimen monitoring:
- annual corrected calcium + intact PTH (Thakker JCEM 2012 surveillance)
- annual fasting gastrin (off PPI where safe) (Thakker JCEM 2012; ENETS)
- annual fasting glucose + insulin + C-peptide + proinsulin (Thakker JCEM 2012)
- annual prolactin + IGF-1 (Thakker JCEM 2012)
- annual chromogranin A as adjunct NET marker (Thakker JCEM 2012; ENETS)
- pituitary MRI ~q3y (or per finding) (Thakker JCEM 2012)
- pancreas MRI/CT +/- EUS q1-3y (Thakker JCEM 2012; ENETS)
- chest CT/MRI for thymic carcinoid q1-2y (Thakker JCEM 2012)
- post-parathyroidectomy calcium + hungry-bone watch then lifelong recurrence surveillance (Thakker JCEM 2012)

Setting (outpatient) monitoring:
- Annual full biochemical screen — Ca/PTH, gastrin, glucose/insulin/proinsulin, prolactin, IGF-1, CgA (Thakker JCEM 2012)
- Pituitary MRI ~q3y; pancreas MRI/CT +/- EUS q1-3y; chest imaging q1-2y (Thakker JCEM 2012)
- Post-op calcium + recurrence surveillance lifelong (Thakker JCEM 2012)

Follow-up plan: Cascade genetic testing + counseling for at-risk first-degree relatives (offer from ~5-10 y of age depending on earliest familial tumor), patient education, smoking cessation (thymic risk), pregnancy planning, and lifelong MEN1-center follow-up (Thakker JCEM 2012)
- Close-out criterion: Cascade screening offered, counseling and follow-up booked

Monitoring phase: Lifelong surveillance — annual calcium/PTH, gastrin, fasting glucose/insulin/proinsulin, prolactin, IGF-1, chromogranin A; periodic pituitary MRI (~3-yearly), pancreas MRI/CT ± EUS (1-3-yearly), chest imaging for thymic carcinoid (1-2-yearly); post-parathyroidectomy hungry-bone and recurrence watch (Thakker JCEM 2012 surveillance schedule)

Disposition

Current setting: outpatient — Confirm/maintain MEN1 diagnosis, run lifelong multi-axis surveillance, coordinate genetic cascade, and select organ-directed therapy

Disposition criteria:
- Continue lifelong multidisciplinary surveillance with documented schedule and follow-up (Thakker JCEM 2012)

Escalation triggers (move to higher acuity):
- Hypercalcemic crisis (Ca >14 / AKI / AMS) -> ED/inpatient (Thakker JCEM 2012)
- Neuroglycopenic insulinoma episode -> inpatient localization + surgery (Thakker JCEM 2012)
- Complicated Zollinger-Ellison (bleed/perforation) -> inpatient + IV PPI (Thakker JCEM 2012)
- Pituitary apoplexy / chiasmal compression -> urgent neurosurgery (Thakker JCEM 2012)

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] MEN1 pHPT with calcium >14 mg/dL and AKI / altered mental status / arrhythmia
- [LIFE_THREATENING] Endogenous hyperinsulinemic hypoglycemia with neuroglycopenic symptoms (confusion, seizure, loss of consciousness)
- [LIFE_THREATENING] Pituitary macroadenoma with apoplexy, acute visual loss, or chiasmal compression

Citations

- 2012 Endocrine Society MEN1 Clinical Practice Guideline (Thakker); 2021-2025 MEN1 surveillance updates [PMID:22723327](https://pubmed.ncbi.nlm.nih.gov/22723327/)
- Cited evidence (PMID 11739416) [PMID:11739416](https://pubmed.ncbi.nlm.nih.gov/11739416/)
- Cited evidence (PMID 23933118) [PMID:23933118](https://pubmed.ncbi.nlm.nih.gov/23933118/)
- Cited evidence (PMID 9103196) [PMID:9103196](https://pubmed.ncbi.nlm.nih.gov/9103196/)
- Cited evidence (PMID 26742109) [PMID:26742109](https://pubmed.ncbi.nlm.nih.gov/26742109/)

Last reconciled with current guidelines: 2026-05-22.
References